Informing Spectroscopists for Over 40 Years

Enhancements to Bruker’s mass spectrometry BioPharma Compass 3.0

Bruker’s mass spectrometry BioPharma Compass 3.0 solution now includes clone selection and MALDI release identity testing to enhance biopharmaceutical characterisation. It supports both high-resolution ESI and MALDI MS, supporting 21 CFR Part 11 compliance. New butterfly plots allow for sub-unit and intact mass analysis for batch-to-batch comparisons, or originator vs biosimilars analysis. Regulated rapid release identity testing employs MALDI to support “pack and fill” QC. Clone screening using intact Fc/2 glycan profiles is performed by MALDI in applications where speed is beneficial.

Request Information about this Product

By submitting this form you agree that we may pass this information to the company who you are enquiring about.